Friday, December 9, 2022, 7:00 PM – 9:00 PM CT (8:00 PM – 10:00 PM ET) – New Orleans, Louisiana

Addressing Current Questions and Controversies in the Management of Multiple Myeloma — What Clinicians Want to Know (Part 3 of a 3-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 64th ASH Annual Meeting

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Hotel Phone: (504) 561-1234

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Celestin Ballroom ABCD (Level 3)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
 
Faculty
Jesús G Berdeja, MD
Director of Multiple Myeloma Research
Tennessee Oncology
Nashville, Tennessee

Rafael Fonseca, MD
Chief Innovation Officer
Getz Family Professor of Cancer
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia


Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi Genzyme.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Front-Line Treatment of Multiple Myeloma (MM)

  • Long-term findings with daratumumab-containing front-line regimens for newly diagnosed MM; role in therapy for patients who are eligible and ineligible for transplant
  • Published data with novel daratumumab-based quadruplet regimens (eg, RVd/daratumumab, KRd/daratumumab) for transplant-eligible patients with newly diagnosed MM; current clinical role and ongoing Phase III evaluation
  • Mechanistic similarities and differences between daratumumab and isatuximab; implications for efficacy and tolerability
  • Key efficacy and safety findings from the Phase III GMMG HD7 trial comparing isatuximab in combination with lenalidomide/bortezomib/dexamethasone (RVd) to RVd alone for transplant-eligible patients with newly diagnosed MM; implications for clinical practice
  • Ongoing Phase III studies of isatuximab as a component of induction therapy for patients eligible and ineligible for transplant
  • Current clinical role of carfilzomib as a component of front-line therapy; implications for routine practice of findings from published studies evaluating carfilzomib-based induction therapy
  • Available data with and current role of minimal residual disease assessment in therapeutic decision-making for patients with MM
  • Optimal approaches to maintenance therapy for transplant-eligible and transplant-ineligible patients, including those who receive daratumumab-based induction regimens
  • Major clinical trial and real-world data sets with oral ixazomib in the induction and maintenance settings; implications, if any, for practice

MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM

  • Mechanism of action of selinexor and published research leading to its initial FDA approval for multiregimen-refractory MM; optimal integration into clinical management algorithms
  • Primary results from the Phase III ICARIA-MM study leading to the initial FDA approval of isatuximab in combination with pomalidomide and dexamethasone for multiregimen-relapsed MM
  • Updated findings from the Phase III IKEMA trial of isatuximab/carfilzomib/dexamethasone for R/R MM; improvement in progression-free survival in comparison to other proteasome inhibitor-containing combinations in the second-line setting
  • Isatuximab for R/R MM: FDA-approved indications, optimal use in clinical practice and ongoing research
  • Key efficacy and safety results from the Phase III BOSTON trial and FDA approval of selinexor in combination with bortezomib/dexamethasone for R/R MM after at least 1 prior therapy; patient selection for this regimen
  • Ongoing investigation of selinexor as a component of other novel combination approaches
  • Biologic rationale for targeting BCMA in MM; structural composition and mechanism of action of the BCMA-directed antibody-drug conjugate belantamab mafodotin
  • Principal efficacy and safety findings with belantamab mafodotin monotherapy for R/R MM; FDA approval and incorporation into routine practice
  • Early data with and ongoing evaluation of belantamab mafodotin in combination with other systemic therapies and/or in earlier lines of treatment
  • Published Phase III data with isatuximab for R/R MM; FDA approval, optimal use in clinical practice and ongoing research

MODULE 3: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM

  • Structural makeup and manufacturing processes of available BCMA-directed CAR T-cell platforms for MM
  • Principal efficacy and safety results from the Phase II KarMMa trial evaluating idecabtagene vicleucel (ide-cel) for R/R MM
  • Key data from the CARTITUDE-1 trial documenting the effectiveness of ciltacabtagene autoleucel (cilta-cel) for pretreated MM
  • FDA approvals of ide-cel and cilta-cel for heavily pretreated, triple-class-exposed MM; optimal selection of patients and timing for CAR T-cell therapy
  • Available data (eg, from the CARTITUDE-2 trial) and ongoing studies (eg, KarMMa-3, KarMMa-4, CARTITUDE-4) evaluating BCMA-targeted CAR T-cell therapies in earlier lines of treatment
  • Incidence, severity and management of class-effect toxicities observed with BCMA-targeted CAR T-cell therapies
  • Early data with and ongoing clinical research evaluating CAR T-cell platforms with targets beyond BCMA

MODULE 4: Bispecific Antibodies in the Treatment of MM

  • Similarities and differences in the cellular targets and mechanisms of action of bispecific antibodies under clinical development for R/R MM
  • Antitumor activity observed with various anti-BCMA bispecific antibodies (eg, teclistamab, elranatamab, REGN5458, TNB-383B) in patients with heavily pretreated MM
  • Antitumor activity observed with teclistamab in the Phase I/II MajesTEC-1 study leading to an FDA breakthrough therapy designation of this agent for R/R MM
  • Rate, depth and duration of responses observed with elranatamab in the pivotal Phase II MagnetisMM-3 trial for R/R MM; FDA fast track designation and potential clinical role
  • Early-phase findings with other promising anti-BCMA bispecific antibody constructs for heavily pretreated MM
  • Biologic rationale for and available efficacy and safety findings with non-BCMA-targeted bispecific antibodies for MM (eg, talquetamab, cevostamab)
  • Spectrum, incidence and severity of toxicities, including cytokine release syndrome and neurotoxicity, with bispecific antibodies in patients with MM; mitigation and management protocols
  • Ongoing clinical research evaluating bispecific antibodies as monotherapy or in combination with other systemic anticancer therapies; optimal selection of patients and timing for enrollment

MODULE 5: Other Investigational Novel Agents for MM

  • Biologic rationale for targeting Bcl-2 in MM; published data with and current nonresearch role of venetoclax-based therapy for patients with MM and translocation 11;14 or Bcl-2 overexpression
  • Design, eligibility criteria and key endpoints of the Phase III CANOVA trial evaluating venetoclax/dexamethasone versus pomalidomide/dexamethasone for R/R t(11;14) MM; other ongoing studies assessing venetoclax-based combinations
  • Mechanism of action of cereblon E3 ligase modulators (CELMoDs; eg, iberdomide, mezigdomide); similarities and differences between CELMoDs and standard immunomodulatory drugs
  • Activity and safety observed with CELMoDs in patients with heavily pretreated MM; ongoing evaluation and potential clinical roles
  • Other promising novel strategies in development for MM

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Customize the selection of first-line therapy for patients with newly diagnosed multiple myeloma (MM), considering new clinical research and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplant.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplantation, and assess when and how this strategy should be integrated into disease management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory (R/R) MM.
  • Understand the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies to facilitate their integration into MM management algorithms.
  • Evaluate the biologic rationale for the use of chimeric antigen receptor (CAR) T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom this novel approach should be considered.
  • Assess available research findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and appropriately refer patients for clinical trials.
  • Recall the design of ongoing studies evaluating novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi Genzyme.

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 561-1234

Meeting Room
Celestin Ballroom ABCD (Level 3)

Directions
Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

There is no fee to participate in this hybrid event. For the in-person symposium in New Orleans preregistration is required as seating is limited.
​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.